

**AMENDMENTS TO THE CLAIMS**

The listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-59. (Canceled).

60. (Previously Presented) A compound which is O-desmethylvenlafaxine succinate.

61. (Previously Presented) The compound of claim 60, wherein the compound is a hydrate of O-desmethylvenlafaxine succinate.

62. (Previously Presented) The compound of claim 61 which is O-desmethylvenlafaxine succinate monohydrate.

63. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

64. (Previously Presented) A pharmaceutical dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

65. (Previously Presented) An oral dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

66. (Previously Presented) The oral dosage form of claim 65, wherein the dosage form is a tablet or capsule.

67. (Previously Presented) The oral dosage form of claim 65, wherein the dosage form is a sustained release formulation.

68. (Previously Presented) The oral dosage form of claim 65, further comprising a rate controlling polymer material.

69. (Currently Amended) The oral dosage form of claim 68, wherein the rate controlling polymer is ~~hydropropylmethyl~~ hydroxypropylmethyl cellulose.

70. (Previously Presented) The oral dosage form of claim 65, wherein the oral dosage form further comprises a binder.

71. (Previously Presented) The oral dosage form of claim 70, wherein the binder is microcrystalline cellulose.

72-78. (Canceled).